American pharma giant Pfizer ($PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded ...

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions.

Pfizer PFE has announced that it is discontinuing development of its oral small molecule GLP-1 agonist, danuglipron, after one patient in a clinical trial experienced a liver injury that could have ...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with the Trump administration, President Donald Trump said Tuesday, as he promised similar deals will be struck with other ...

WASHINGTON (AP) — Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Yet another experimental drug heavily touted by Pfizer Inc. has foundered in advanced testing, raising worries about productivity ...

According to healthcare research firm 3 Axis Advisors, drugmakers are planning to raise U.S. prices on medications including ...

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader ...